Confusion matrix illustrating predictions on an extended dataset, including CNS tumors, breast cancer, lung cancer and melanoma CNS metastases (91 CNS classes and 2,801 samples; three metastatic classes and 85 samples). Using 7,500 CpGs, MethyLYZR achieves an accuracy of 90.31%, 89.39%, 88.76% and 99.99% in distinguishing among breast, lung, melanoma and CNS samples, respectively.
